4//SEC Filing
Hegde Priti 4
Accession 0001104659-23-078201
CIK 0001621227other
Filed
Jul 4, 8:00 PM ET
Accepted
Jul 5, 5:05 PM ET
Size
12.8 KB
Accession
0001104659-23-078201
Insider Transaction Report
Form 4
Hegde Priti
Director
Transactions
- Award
Option to Purchase Ordinary Shares
2023-07-05+152,376→ 152,376 totalExercise: $0.11Exp: 2032-12-14→ Ordinary Shares (152,376 underlying) - Award
Option to Purchase Ordinary Shares
2023-07-05+226,464→ 226,464 totalExercise: $1.77Exp: 2031-08-24→ Ordinary Shares (226,464 underlying) - Award
Option to Purchase Ordinary Shares
2023-07-05+109,746→ 109,746 totalExercise: $0.57Exp: 2031-12-08→ Ordinary Shares (109,746 underlying)
Footnotes (8)
- [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an "Ordinary Share") (each such option, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the "Ordinary Share Exchange Ratio").
- [F2]The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.
- [F3]The exercise price was converted from GBP1.39, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F4]Currently exercisable as to 127,386 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 7,077 Ordinary Shares on the twenty-fifth of each month from July 25, 2023 through August 25, 2024.
- [F5]The exercise price was converted from GBP0.46, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F6]Currently exercisable as to 48,006 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 3,430 Ordinary Shares on the first of each month from August 1, 2023 through January 1, 2025.
- [F7]The exercise price was converted from GBP0.09, based on an exchange rate of $U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F8]Will be exercisable as to 38,094 Ordinary Shares on December 15, 2023 and will be exercisable as to the remainder in monthly installments of 4,758 Ordinary Shares on the fifteenth of each month from January 15, 2024 through November 15, 2025 and 4,848 Ordinary Shares on December 15, 2025.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeother
Related Parties
1- filerCIK 0001880034
Filing Metadata
- Form type
- 4
- Filed
- Jul 4, 8:00 PM ET
- Accepted
- Jul 5, 5:05 PM ET
- Size
- 12.8 KB